| Q37630254 | A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis. |
| Q38666266 | A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses |
| Q39456569 | A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis |
| Q53791744 | A Step toward an Optimized Rifampin Dose Completed. |
| Q58578267 | A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs |
| Q28602112 | A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP) |
| Q98563422 | A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis |
| Q91742553 | Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs |
| Q35963971 | Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients |
| Q38533435 | Antituberculosis drugs in children |
| Q36540902 | Are the Present Doses of Anti Tubercular Drugs Adequate for Severe Disease? |
| Q47312168 | Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling |
| Q36319854 | Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey |
| Q36730088 | Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease |
| Q51092138 | CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. |
| Q36157986 | Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? |
| Q39062016 | Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen. |
| Q42688154 | Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough? |
| Q64072704 | Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis |
| Q89748743 | Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions |
| Q91611591 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis |
| Q60364142 | Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! |
| Q89315356 | Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial |
| Q54996259 | Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. |
| Q38724073 | Emerging drugs and alternative possibilities in the treatment of tuberculosis |
| Q26771997 | Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? |
| Q36115081 | Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial |
| Q36253299 | Finding the right dose of rifampicin, and the right dose of optimism |
| Q64912442 | Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin. |
| Q33843657 | Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis |
| Q93221164 | High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease |
| Q64095041 | High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre |
| Q37507802 | High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial |
| Q38777021 | Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods. |
| Q28607283 | In silico evaluation and exploration of antibiotic tuberculosis treatment regimens |
| Q92966991 | In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis |
| Q92638344 | Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons |
| Q40444755 | Innovative Methods to Manage, Detect, and Prevent Tuberculosis. |
| Q30251497 | Insights into the pharmacokinetic properties of antitubercular drugs. |
| Q92756083 | Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing |
| Q88383639 | Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis |
| Q40226194 | Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. |
| Q36438900 | Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction |
| Q92264474 | Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture |
| Q38754367 | New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response |
| Q90286792 | Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis |
| Q93171585 | Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis |
| Q49825374 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria |
| Q64251790 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India |
| Q38865905 | Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. |
| Q40330811 | Oxidative stress and TB outcomes in patients with diabetes mellitus? |
| Q40192322 | Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis |
| Q30377051 | Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration |
| Q47332682 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? |
| Q58611011 | Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania |
| Q36730120 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. |
| Q52559111 | Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. |
| Q89699857 | Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF) |
| Q38852090 | Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. |
| Q52684511 | Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay. |
| Q36644907 | Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa |
| Q40571190 | Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. |
| Q50207282 | Pound foolish and penny wise-when will dosing of rifampicin be optimised? |
| Q96162630 | Preclinical models to optimize treatment of tuberculous meningitis - A systematic review |
| Q33595569 | Predictors of delayed culture conversion among Ugandan patients |
| Q91728034 | Protocol, rationale and design of PEOPLE (Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar): a cluster randomized trial on effectiveness of different modalities of implementation of post-exposure prophylaxis of leprosy contacts |
| Q53692275 | Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. |
| Q45237067 | Reply to Alffenaar et al. |
| Q54296806 | Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?" |
| Q28828720 | Repurposing clinically approved cephalosporins for tuberculosis therapy |
| Q40095703 | Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? |
| Q38857578 | Rifamycins, Alone and in Combination |
| Q44331084 | Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs |
| Q30377066 | Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. |
| Q38635790 | Synthetic investigational new drugs for the treatment of tuberculosis |
| Q55232003 | The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. |
| Q28598393 | The best of respiratory infections from the 2015 European Respiratory Society International Congress |
| Q92914751 | The evolving research agenda for paediatric tuberculosis infection |
| Q57152709 | The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes |
| Q38676708 | The paradigm shift to end tuberculosis. Are we ready to assume the changes? |
| Q56969466 | Toxicity associated with tuberculosis chemotherapy in the REMoxTB study |
| Q36094210 | Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
| Q52680275 | Treatment of Tuberculous Meningitis and Its Complications in Adults. |
| Q64233651 | Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening |
| Q57235679 | Tuberculosis |
| Q92572130 | Tuberculosis |
| Q30248788 | Tuberculosis therapy for 2016 and beyond |
| Q38378992 | Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies |
| Q47192301 | Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe. |
| Q33735642 | Update in Mycobacterium tuberculosis lung disease 2014. |
| Q28387739 | Update in Tuberculosis/Pulmonary Infections 2015 |
| Q36036963 | Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study |
| Q36242447 | Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies |